Evolus, Inc. (NASDAQ:EOLS) Insider David Moatazedi Sells 6,251 Shares

Evolus, Inc. (NASDAQ:EOLS) insider David Moatazedi sold 6,251 shares of the company’s stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the sale, the insider now directly owns 508,619 shares in the company, valued at $6,306,875.60. This trade represents a 1.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Evolus Trading Down 1.6 %

NASDAQ:EOLS opened at $12.05 on Friday. Evolus, Inc. has a 12 month low of $9.25 and a 12 month high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The company has a 50-day moving average price of $13.66 and a 200-day moving average price of $13.80. The stock has a market cap of $766.22 million, a price-to-earnings ratio of -13.24 and a beta of 1.28.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price target on shares of Evolus in a report on Wednesday, March 5th. HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research report on Wednesday, March 5th. Finally, Barclays increased their target price on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th.

Institutional Trading of Evolus

Large investors have recently bought and sold shares of the company. KBC Group NV purchased a new position in shares of Evolus in the 4th quarter valued at approximately $49,000. IFP Advisors Inc lifted its position in Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after buying an additional 4,709 shares during the period. Point72 Asset Management L.P. purchased a new position in Evolus during the third quarter valued at $132,000. KLP Kapitalforvaltning AS bought a new stake in shares of Evolus during the 4th quarter valued at $106,000. Finally, Rafferty Asset Management LLC purchased a new stake in shares of Evolus in the 4th quarter worth about $115,000. 90.69% of the stock is owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.